In:
Oncology, S. Karger AG, Vol. 84, No. 6 ( 2013), p. 342-349
Abstract:
〈 b 〉 〈 i 〉 Objectives: 〈 /i 〉 〈 /b 〉 A phase II study was performed to investigate the safety and efficacy of concurrent chemoradiotherapy (CCRT) combined with an orally active fluoropyrimidine, S-1, plus cisplatin for locally advanced esophageal cancer (LAEC). 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 CCRT comprised 2 courses, a 30-Gy radiotherapy over 3 weeks plus daily oral S-1 (80 mg/m 〈 sup 〉 2 〈 /sup 〉 /day) for 2 weeks and a 24-hour cisplatin infusion (70 mg/m 〈 sup 〉 2 〈 /sup 〉 ) on day 8, and an identical course administered after a 2-week break. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 One hundred and sixteen patients, 12 with stage II, 71 with stage III, and 33 with stage IVa LAEC participated, and 106 of them (91.4%) completed the CCRT course. The most serious toxicity was myelosuppression: grade 3 and 4 neutropenia occurred in 28.4 and 9.5% of patients, respectively. Nonhematologic toxicity was moderate. Complete response rates in patients with stage II, III, and IVa LAEC were 91.7, 67.6, and 36.4%, respectively. The overall median survival time 〈 b 〉 〈 /b 〉 was 2.3 years and that of patients with stage II, III, and IVa cancer was 7.0, 2.6, and 1.3 years, respectively. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 CCRT combined with S-1 plus cisplatin showed promising safety and efficacy. Potentially, this combination therapy could become a baseline medication for patients with LAEC.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2013
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink